According to the National Agency for Drug Safety (Agence nationale de sécurité du médicament et des produits de santé, ANSM), there are currently four treatments available through the early access (accès précoce) scheme for patients at high risk of severe forms of Covid-19, namely Xevudy (sotrovimab), Paxlovid (nirmatrelvir/ritonavir), Ronapreve (casirivimab/imdevimab) and Evusheld (tixagevimab/cilgavimab).
More than 16,000 requests to use Ronapreve to prevent or treat Covid-19 have been accepted since the drug was granted early access, while 14,000 requests to use Evusheld for the prevention of Covid-19 have been accepted.
For the two curative treatments Xevudy and Paxlovid, both granted early access to treat Covid-19 in early 2022, a total of 4,257 and 1,500 usage requests, respectively, have so far been authorised.
Source:
https://ansm.sante.fr, “Point sur l’utilisation des traitements contre le Covid-19 disponibles en accès précoce”, 24th February 2022